
IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.

IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.

Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

Dr. Shirley D’Sa discusses how treatment strategies for WM have evolved over the course of her career.

Arterial thrombosis may occur years before cancer diagnosis, suggesting it could be a risk factor, according to Dr. Tiziano Barbui.

Proton therapy may reduce urinary, bowel and sexual side effects in prostate cancer by minimizing radiation exposure to healthy tissue, per Dr. Curtiland Deville Jr.

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease stage and type.

Dr. Kara Kelly discusses specific long-term health considerations that AYA survivors of lymphoma should be aware of to best prepare for survivorship.

Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.

Researchers followed patients for years and found that the risk of dying from prostate cancer depended on how aggressive the cancer was at diagnosis.

Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.

The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.

For Melanoma Awareness Month, Dr. Douglas Johnson explains how stage and features of the disease can guide treatment decisions after diagnosis.

Dr. Andrew M. Evens breaks down what it means to be an adolescent or young adult with lymphoma and how treatment differs from pediatric and adult care.

Dr. Kara Kelly discusses some of the most common challenges faced by adolescent and young adult patients with lymphoma.

Dr. Daniel J. Boffa shared how cancer care teams support patients in quitting smoking and how new data may guide improvements in high-smoking U.S. regions.

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.

Immune therapy is generally safer than chemotherapy, allowing more patients with melanoma and other conditions like heart or lung issues receive treatment.

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.

Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenström macroglobulinemia early on and how to treat it.

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer.

Dr. Scott T. Tagawa discusses what patients with prostate cancer should know about the potential benefits and risks of participating in a clinical trial.

Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.

Dr. Neha Mehta-Shah discusses ways patients with rare blood cancers, such as lymphoma, can better understand their specific subtype of disease.

Patient and disease-related factors influence surgical recovery and treatment outcomes after Keytruda and Padcev in advanced urothelial cancer.

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer.

Breast MRI helps doctors detect disease in newly diagnosed and high-risk patients without replacing mammograms, according to an expert.

Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.

Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.

CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.